We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,054

Compensatory Damages Allowed to Stand in Depakote Trial, Despite Adequate Warnings and Lack of Warnings Causation
  • Reed Smith LLP
  • USA
  • August 11 2017

We are beginning to feel like the Drug and Device Law theatre critic. Or perhaps we should say “theatre cheerleader,” as we rarely wax critical (at


The Luck of The Draw: A Strong Preemption Ruling from an Anticoagulant MDL
  • Reed Smith LLP
  • USA
  • August 9 2017

We have offered our view that cases seeking to impose liability based on well-known risks found with an entire class of prescription medications tend


Comment K and Non-Implanted Medical Devices
  • Reed Smith LLP
  • USA
  • August 4 2017

About two years ago, in our post "How Does a Bad Idea Get Implanted," we discussed what at the time seemed a California peculiar argument that the


Post-BMS Personal Jurisdiction Cheat Sheet
  • Reed Smith LLP
  • USA
  • July 31 2017

In the wake of the defense wins during the last Supreme Court term in Bristol-Myers Squibb Co. v. Superior Court, 137 S.Ct. 1773 (2017) ("BMS"), and


Causation Testimony Excluded as “Unhelpful” and “Unreliable” in Heart-Lung Machine Death Case
  • Reed Smith LLP
  • USA
  • July 28 2017

One of the wonders of parenthood is its ability to deliver interludes so sublime in their exquisite simplicity that they provoke smiles long after


Plaintiff’s Expert’s Opinions Trimmed Post-Remand in Mesh Litigation
  • Reed Smith LLP
  • USA
  • July 27 2017

There is always a level of uncertainty when a case gets remanded from an MDL. New judge; new interpretations of prior rulings; new rulings. It can be


Guest Post - Causation or No Causation, That Is the Question.
  • Reed Smith LLP
  • European Union, France
  • July 26 2017

Today we feature another guest post from our European correspondents, Reed Smith partner Marilyn Moberg and associate Kathryn Bond. There has been


PhRMA Comment on the FDA’s Proposed Off-label Rule: The Rule of Law is the Best Medicine
  • Reed Smith LLP
  • USA
  • July 25 2017

The FDA cannot get out of its own way on the issue of off-label communications. Its power to punish off-label promotion comes from an odd regulatory


Artificial Intelligence and Learned Intermediaries
  • Reed Smith LLP
  • USA
  • July 24 2017

In the July 7, 2017, "Artificial Intelligence" issue of Science, we were intrigued by a short piece in the "Insights" section on "Artificial


Guest Post West Virginia Court Finds Both Fraudulent Joinder & Misjoinder in Opioid Action
  • Reed Smith LLP
  • USA
  • July 21 2017

What follows is a guest post from long-time friend of the blog Thomas J. Hurney, Jr. of Jackson Kelly PLLC in Charleston, West Virginia. Tom comes to